Erudio Healtherudio.com
Drug
Calderasib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying calderasib: KANDLELIT-001. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| KANDLELIT-001 NCT05067283 · Merck Sharp & Dohme LLC | KRAS G12C-mutant advanced solid tumors | Phase 1 | 52 | 18 | Focused | Oct 31, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| KANDLELIT-004 NCT06345729 · Merck Sharp & Dohme LLC FocusedView → | KRAS G12C-mutant NSCLC with PD-L1 TPS ≥50% | Phase 3 | Focused | View | |||
| KANDLELIT-007 NCT07190248 · Merck Sharp & Dohme LLC FocusedView → | first-line KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC | Phase 3 | Focused | View | |||